AndyForce Develops 'Fusion Kit' Capable of Simultaneous COVID-19 and Influenza Diagnosis

[Asia Economy Reporter Hyunseok Yoo] AndyForce announced on the 29th that it has successfully developed two types of molecular diagnostic kits capable of simultaneously diagnosing COVID-19 and influenza: the molecular diagnostic kit ‘ND COVID-19 Flu’ and the rapid diagnostic kit ‘ND COVID-19 Flu Rapid kit.’

The newly developed molecular diagnostic kit can diagnose influenza types A and B as well as the COVID-19 virus all at once. To enhance the convenience and accuracy of COVID-19 diagnosis, three gene (E, RdRp, N) testing methods were introduced. The rapid diagnostic kit can quickly diagnose influenza and COVID-19 simultaneously and is composed of a single cassette.

AndyForce’s molecular diagnostic kit can produce results within 2 hours using the RT-PCR method. The rapid diagnostic kit can deliver results within 15 minutes, and it is expected to have high demand from overseas countries seeking low-cost and rapid diagnosis.

With this product development, AndyForce has expanded its COVID-19 diagnostic kit production platform to include ▲RT-PCR ▲immunodiagnosis ▲antigen diagnosis ▲influenza diagnosis.

An AndyForce official stated, “With the development of this diagnostic kit, we are prepared for a second COVID-19 pandemic and expect to conveniently and accurately distinguish between COVID-19 and influenza patients during this winter’s flu season.” He added, “We plan to pursue export approval from the Ministry of Food and Drug Safety and conduct clinical trials at domestic university hospitals.” He further noted, “This is a converged new product that maximally integrates the advantages and technology of antigen diagnostic kits, and it will be exported overseas along with existing products.”

This content was produced with the assistance of AI translation services.